The FDA will hold an advisory panel for Eli Lilly's Alzheimer drug donanemab, delaying approval beyond the first quarter. Lilly stock fell.

Successful investor Mario Gabelli attained billionaire status primarily by investing his and his client's money. He became well-known in the 1980s for making successful picks in media and telecom s...

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Eli Lilly said on Thursday it has found bacteria and high levels of impurities in products claiming to be compounded versions of tirzepatide, the active ingredient in its popular diabetes drug Moun...

Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.

Eli Lilly (LLY) will likely not meet the demand for diabetes and weight loss drugs in 2024. The Eli Lilly CFO noted that increases in production capacity will take time.

Eli Lilly and Co (NYSE:LLY ) Cowen's 44th Annual Health Care Conference March 6, 2024 9:10 AM ET Company Participants Anat Ashkenazi - EVP & CFO Andrew Adams - Vice President of New Therapeutic Mod...

Seriously, how much longer before Nvidia (NASDAQ: NVDA ) overtakes Microsoft (NASDAQ: MSFT ) as the most valuable company in the world? The chipmaker just surpassed Saudi Aramco to become the third...

Investors are excited about the opportunity for Viking's experimental weight-loss drug VK2735. Viking doesn't compare favorably against Lilly and Novo Nordisk in most categories.

Eli Lilly and Novo Nordisk stock each rose over 50% in 2023 thanks to their diabetes treatments. Industry research suggests the diabetes market will continue to grow for decades to come.

Anti-obesity medicines are currently a tremendously lucrative market. Viking Therapeutics is ascendant after publishing strong phase 2 data.

In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.

Blockbuster drugs can be disproportionately beneficial for biopharmas. Novo Nordisk is already squeezing a lot of cash out of semaglutide.

Eli Lilly's prospects look solid thanks to a key medicine, a solid lineup, and a deep pipeline. Viking Therapeutics' shares could skyrocket (again) on positive clinical developments.

Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.